Pharmaceutical class: Vedolizumab is a gut selective biological immunosuppressant
Active compound: vedolizumab
SmPC: Click here for Entyvio 108 mg, solution for sub cutaneous injection
SmPC: click here for Entyvio 300 mg, solution for intravenous injection
Therapeutic indications:
Ulcerative colitis
Treatment of moderate to severe active ulcerative colitis in adult patients with insufficient response or loss of response or intolerance to conventional therapy or anti TNF (tumor necrosis factor alpha antagonist) therapy.
Crohn's disease
Treatment of moderate to severe active Crohn's disease in adult patients with insufficient response or loss of response or intolerance to conventional therapy or with anti TNF (tumor necrosis factor alpha antagonist) therapy.
Posology
Induction phase
Ulcerative colitis
The recommended dosage regimen for intravenous vedolizumab is 300 mg administered by intravenous infusion at 0, 2 and 6 weeks, then every 8 weeks.
Crohn's disease
The recommended dosage regimen for intravenous vedolizumab is 300 mg administered by intravenous infusion at 0, 2 and 6 weeks, then every 8 weeks.
Maintenance phase
Ulcerative colitis and Crohn's disease
The recommended dosing regimen for
- intravenous vedolizumab: every 8 weeks after induction phase
- Vedolizumab subcutaneously as maintenance therapy after at least 2 intravenous infusions is 108 mg administered by subcutaneous injection once every 2 weeks. The first subcutaneous dose should be given instead of the next scheduled intravenous dose, then every 2 weeks thereafter.
Prices
Entyvio 300 mg: click here for information
Entyvio 108 mg: click here for information
Reimbursment
Entyvio IV: CIVARS
Entyvio SC: CIVARS or paper version
Practical help with the ELECTRONIC REIMBURSEMENT REQUEST from Entyvio